Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells. by Alberti, L. et al.
RESEARCH ARTICLE
Different Effects of BORIS/CTCFL on
Stemness Gene Expression, Sphere Formation
and Cell Survival in Epithelial Cancer Stem
Cells
Loredana Alberti1, Lorena Losi2, Serge Leyvraz3, Jean Benhattar1,4*
1 Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland, 2 Department of Life
Sciences, University of Modena and Reggio Emilia, Modena, Italy, 3 Department of Oncology, Lausanne
University Hospital, Lausanne, Switzerland, 4 Biopath Lab, Lausanne, Switzerland
* jean.benhattar@gmail.com
Abstract
Cancer stem cells are cancer cells characterized by stem cell properties and represent a
small population of tumor cells that drives tumor development, progression, metastasis and
drug resistance. To date, the molecular mechanisms that generate and regulate cancer
stem cells are not well defined. BORIS (Brother of Regulator of Imprinted Sites) or CTCFL
(CTCF-like) is a DNA-binding protein that is expressed in normal tissues only in germ cells
and is re-activated in tumors. Recent evidences have highlighted the correlation of BORIS/
CTCFL expression with poor overall survival of different cancer patients. We have previ-
ously shown an association of BORIS-expressing cells with stemness gene expression in
embryonic cancer cells. Here, we studied the role of BORIS in epithelial tumor cells. Using
BORIS-molecular beacon that was already validated, we were able to show the presence
of BORISmRNA in cancer stem cell-enriched populations (side population and spheres) of
cervical, colon and breast tumor cells. BORIS silencing studies showed a decrease of
sphere formation capacity in breast and colon tumor cells. Importantly, BORIS-silencing led
to down-regulation of hTERT, stem cell (NANOG,OCT4, SOX2 and BMI1) and cancer stem
cell markers (ABCG2, CD44 and ALDH1) genes. Conversely, BORIS-induction led to up-
regulation of the same genes. These phenotypes were observed in cervical, colon and inva-
sive breast tumor cells. However, a completely different behavior was observed in the non-
invasive breast tumor cells (MCF7). Indeed, these cells acquired an epithelial mesenchymal
transition phenotype after BORIS silencing. Our results demonstrate that BORIS is associ-
ated with cancer stem cell-enriched populations of several epithelial tumor cells and the dif-
ferent phenotypes depend on the origin of tumor cells.
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Introduction
Enormous evidences support the view that human cancer could be considered as a stem cell
disease [1–3]. The cancer stem cells (CSCs) theory assumes that cancers are viewed as complex
tissues where aberrant cell growth is driven by a small population of cells defined as tumor-ini-
tiating cells. These cells are characterized by three main properties: uncontrolled proliferation
capacity, ability of self-renewal and ability to differentiate into a non-CSC progeny [3, 4]. Inter-
estingly, the properties of these malignant cells are closely similar to the three features that
characterize normal stem cells: the potential to proliferate extensively, the self-renewal and the
capability to develop into multiple lineages. Accordingly, tumor cells with these properties are
also called cancer stem cells. The first observations of the presence of CSCs were performed in
human acute myeloid leukemia [5] and consequently developed in different types of human
solid tumors, as breast [6], brain [7], colon [8, 9], pancreatic [10] and ovarian [11] tumors. It
has been shown that many cancer patients, especially with solid tumors, respond poorly to con-
ventional therapies, such as chemotherapy and radiotherapy, and after an initial partial remis-
sion, tumors relapse. The reasons of such failure could be explained by the drug- and radio-
resistance of CSCs. In addition, it has been demonstrated that CSCs are more frequent in
highly aggressive and refractory tumors [6–7]. Therefore, it becomes extremely important to
identify the CSC populations and their markers to develop CSC-targeted therapies to overcome
the resistance of CSCs to the conventional anti-cancer drugs. Using experimental approaches,
the CSCs of many tumor types have been characterized phenotypically and several CSC mark-
ers have been identified [4, 12]. However, most of the identified markers are not fully specific
to CSCs because they are also expressed in normal cells, and therefore, the use of multiple
markers is required. Many efforts on cancer research will be necessary to optimize targeting
CSCs therapies. There are several approaches to enrich the CSCs populations, which are mainly
used for in vitro analyses and screening methods. One approach is based on the selection of a
cell subpopulation that is able to efflux dyes. The efflux of these dyes is a capacity of CSCs
which express genes encoding the ATP-binding cassette (ABC) drug transporters, such as
ABCG2 [13–15]. The most used dye is Hoechst 33342, which is a DNA-binding dye. The sub-
population selected by this method is called side population (SP). The aldehyde dehydrogenase
(ALDH) activity is another functional property of stem cells, used to isolate enriched CSCs
population [16, 17]. An additional in vitro approach is based on non-adherent serum-free cul-
ture [8, 18]. Using this method, the cells from different type of tumors (including brain, breast
and colon), which have the capacity of self-renewal and to maintain stem-cell properties, can
form spheroid colonies named spheres [19].
BORIS (Brother of Regulator of Imprinted Sites) is a DNA-binding protein which shares
with its paralog CTCF, an 11 zinc-finger domain, thus also called CTCFL (CTCF-like) [20].
BORIS protein is involved in epigenetic reprogramming and it belongs to cancer testis antigen
family, as it is expressed in normal germinal cells and reactivated in tumors. Recent reports
indicate that BORIS expression is associated with advanced stage in different cancers, such as
ovarian, prostate, esophageal and hepatocellular cancers [21–24]. In ovarian cancers, BORIS
expression may also confer poor prognosis [21]. Our previous study has demonstrated the
association of BORIS expression with stem cell and CSC marker genes in embryonic carcinoma
cells [25]. Altogether these evidences prompted us to further investigate the presence and the
molecular functions of BORIS in the CSCs-enriched populations in other types of tumor cells
and specifically in cervical, colon and breast tumor cells. As there is not yet a validated antibody
against BORIS, we used the BORIS-molecular beacon (BORIS-MB) that was previously tested
and validated for in vivo detection of BORISmRNA [25]. BORIS-MB allowed us to visualize
the BORIS-positive cells in the analyzed epithelial tumor cells. Interestingly, we found that
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BORIS is highly expressed in CSC-enriched populations isolated from SP and spheres. Further-
more, functional studies revealed that BORIS could play an important role in the self-renewal
of tumors and in the acquisition of epithelial mesenchymal transition (EMT) signature in base
of the origin of the tumor cells.
Materials and Methods
Cells and spheres preparation
The human cell lines (HeLa, cervical adenocarcinoma; HT29, colon adenocarcinoma; NCCIT,
embryonic carcinoma) were purchased from the American Type Culture Collection (ATCC)
and the human breast cell lines (MCF7 and MDA-MB-231) were provided by Dr Stéphanie
Renaud (Biotechnology Institute, University of Lausanne). The cells were cultured at 37°C
with 5% CO2 either in Dulbecco's modified Eagle's medium (DMEM; Gibco, Invitrogen) for
HeLa and HT29 cells, or in RPMI-1640 medium (Gibco, Invitrogen) for NCCIT, MCF7 and
MDA-MB-231 cells, supplemented with 10% of heat inactivated fetal bovine serum (FBS; Invi-
trogen) and 1% of Penicillin-Streptomycin (Gibco, Invitrogen).
For sphere culture, cells (HT29, MCF7 and MDA-MB-231) were first detached with 0.25%
trypsin solution (Invitrogen) and washed twice in PBS (Invitrogen). Then, cells were filtrated
twice using a cell-strainer of 40 μmmesh size (Falcon) and cultured in serum-free medium
containing DMEM/F-12 medium (Invitrogen) supplemented with B27 (Invitrogen), 5 μg/ml
heparin (Sigma), 20 ng/ml EGF (Epidermal Growth Factor, BD Biosciences), 20 ng/ml FGF
(Fibroblast Growth Factor, BD Biosciences) and 5 μg/ml insulin (Sigma). Cells were plated into
ultra-low attachment 6-well plates (Corning) at the density of 1,000 cells/ml for 10–15 days.
Spheres were counted and collected for RNA extraction. An aliquot of spheres was seeded in
normal medium with serum to allow the differentiation.
Fluorescence analysis using BORIS-MB
Cells were prepared as previously described [25]. Briefly, cells in suspension (1 x 106 cells/ml)
were incubated at 37°C for 1.5 hour in serum-free DMEMmedium with Cy3-BORIS MB
(200 nM) and Hoechst 33342 (5 μg/mL) in presence of a Lipofectamine RNAiMAX siRNA
transfection reagent (Invitrogen). The cells were washed, resuspended in PBS—5 mM EDTA
and cytocentrifugated onto glass slide using a cytospin centrifuge and then examined under a
fluorescent (Axioplan2 Imaging, Zeiss) or a confocal (LSM 710 Quasar, Zeiss) microscope.
For ABCG2 fluorescence staining, cells were prepared as described beyond. After cytospin,
cells were fixed with ice-cold acetone for 8 min and stained at 4°C overnight with rabbit anti-
human ABCG2 antibody (Sigma) used at 1:20 dilution in PBS. Slides were washed with PBS
and incubated for 1 hour at room temperature with donkey anti-rabbit secondary antibody
labeled with Alexa Fluor 488 (Sigma) used at 1:500 dilution in PBS. The slides were then exam-
ined under fluorescent microscope.
FACS analysis and sorting of SP
HeLa cells (1 x 106 cells/ml) were incubated in serum-free medium at 37°C for 1.5 hour with
Hoechst 33342 (Invitrogen) at a final concentration of 12.5 μg/ml either alone or in combina-
tion with 50 μM verapamil (Sigma) as a control. The cell suspensions were periodically mixed
during the incubation. After incubation, cells were washed with PBS and resuspended in PBS—
5 mM EDTA. Before the analysis, the cells were incubated with propidium iodide (2 μg/ml)
and filtrated using a cell-strainer of 40 μmmesh size (Falcon). SP analyses were performed
using LSRII (Becton Dickinson) and the sorting of SP and NSP (non-SP) using FACS Aria
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(Becton Dickinson) at the facility of EPFL (Ecole Polytechnique Fédérale of Lausanne).
Hoechst 33342 dye was excited at 355 nm and its fluorescence was analyzed using dual-wave-
length of emission, 445 nm for Hoechst blue and 650 nm for Hoechst red.
Ectopic BORIS expression
Hela cells were transfected with pCMV-BORIS plasmid using Lipofectamine 2000 transfection
reagent (Invitrogen) as previously described [25].
BORIS knockdown by inducible shRNA lentiviral system
Stables cell lines with inducible expressing shRNAs targeting human BORISmRNA were pre-
pared as previously described [25]. HeLa, HT29, MCF7 and MDA-MB-231 tumor cell lines
were used in these experiments.
BORIS cDNA expression by inducible lentiviral system
Stable cell lines with inducible expressing human BORIS cDNA were generated using the doxy-
cycline-inducible lentiviral system [26]. BORIS cDNA from pCMV-BORIS plasmid was cloned
into pINDUCER20 by Gateway Cloning system (Invitrogen). The lentiviral vector pINDU-
CER20 contains the antibiotic selection marker of G418 (Geneticin), which enables to select
only the transduced cells. This vector also contains a cassette with a doxycycline-inducible pro-
moter that controls the transcription of the cloned cDNA. For the generation of lentivirus, we
followed our procedure as previously described [25]. The viral suspension combined with
8 μg/ml polybrene (Sigma) was used to infect target cells (HeLa, HT29, MCF7 and MDA-MB-
231). Twenty-four hours post infection the medium was replaced with medium supplemented
with 500 μg/ml G418 (Roche). After 2 weeks of antibiotic selection, 2 μg/ml of doxycycline
(Sigma) was added to the medium to allow induction of BORIS cDNA expression and doxycy-
cline-containing medium was refreshed every 3 days.
Quantitative RT-PCR analysis
qRT-PCR analyses were performed as previously described [25]. The ΔΔCt method was used
to determine the relative expression levels, which were normalized to GAPDH level. As already
reported [25], for all the amplified target genes PCR efficiency extended from 94 to 101%, with
correlation coefficient (r2) ranging from 0.96 to 1.0. The Ct values of GAPDHmeasured the
similar levels (Ct = 10.07 ± 0.25) for all the analyzed cells.
The sequences of primer used in addition are shown in S1 Table.
CD44+/CD24- analysis by flow cytometry
CD44+/CD24- expression was analyzed in cells engineered to stably exhibit knockdown
BORISmRNA or express BORIS cDNA. Cells were trypsinized and 106 cells were resuspended
in 100 μL PBS-1% FBS. Monoclonal mouse anti-human CD44–APC-H7 antibody (BD Phar-
mingen) and a monoclonal mouse anti-human CD24–Alexa Fluor 647 antibody (BD Pharmin-
gen) were added at dilutions of 1:20 and 1:5 respectively, as suggested by the manufacturer,
and incubated for 40 min at 4°C. DAPI was added at concentration of 1 μg/ml during the last
10 min of incubation. After washing with PBS-1% FBS, flow cytometry analysis were per-
formed using Gallios flow cytometer (Beckman Coulter). At least 5 x 104 events were counted
for all samples. The analysis of percentage of CD44+/CD24- cells was estimated after excluding
dead cells (DAPI positive cells) and gating on eGFP and tRFP positive cells. The results were
analyzed using FlowJo software. Three independent experiments were performed.
BORIS/CTCFL in Human Cancer Stem Cells
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Colony forming assay
Cells were trypsinized and resuspended in medium. Three hundred cells were seeded in 6 well/
plates in triplicates. Cells were cultured in freshly doxycycline-containing medium. After 2
weeks, cells were fixed with 1 ml of 4% formaldehyde for 10 min at room temperature and
stained with 1 ml of 0.1% crystal violet for 10 min. After washing with PBS, each well was pho-
tographed and the colonies (determined as>50 cells/colony) were counted using ImageJ
program.
Migration assay
Cell migration was determined using cell culture inserts (BD Falcon) with 8 μm pore size.
Briefly, the cells were harvested and resuspended in serum-free medium, 5 x 104 cells were
plated into the top of inserts placed in 24-well plates. At the bottom well of the inserts were
added 500 μL medium supplemented with 10% FBS. After 48 hours of incubation, the non-
migrating cells were removed with a cotton swab and the migrating cells (on the lower surface
of the insert) were fixed with 1 ml of 4% formaldehyde and then stained with 1 ml of 0.1% crys-
tal violet for 10 min. After washed 3 times with PBS, the migrating cells were counted under
ten random high-power microscopic fields per insert and the mean number of migrating cells
was calculated for each group of cells.
Cell proliferation and chemo-sensitivity assays
Cell proliferation analysis after BORIS silencing and BORIS induction were assessed by MTT
assay as previously described [25].
In vitro growth effect of 5-Fluorouracil (5-FU) was determined by MTT assay. Briefly, each
group of cells, after BORIS silencing, was seeded in triplicate at the density of 1 x 104 cells/well
in 96-well plates in doxycycline-containing medium. The day after, 5-FU (Sigma) was added at
different concentrations: 0.5, 5, 50 and 500 μg/ml. Cells were incubated for 2 days and then cell
viability was measured by MTT assay. Growth inhibition or surviving fraction was expressed
as a percentage of the untreated controls that were measured at once, using the equation:
(absorbance of treated sample/absorbance of untreated sample) x 100.
Statistical analysis
Statistical significance was evaluated using two-tailed student t-test analysis. P-value<0.05 was
considered statistically significant.
Results
BORISmRNA is expressed in side population cells
To investigate the presence of BORISmRNA in CSC-enriched populations of epithelial tumor
cells, we used as models the human HeLa (cervical), HT29 (colon), MCF7 (non-invasive
breast) and MDA-MB-231 (invasive breast) tumor cell lines. Expression analysis showed a
lower level of BORISmRNA in HeLa and HT29 compared to embryonic tumor cells (NCCIT),
while in MCF7 and MDA-MBA-231 cells BORISmRNA was almost undetectable (Fig 1A).
Therefore, HeLa, HT29, MCF7 and MDA-MBA-231 tumor cells can be classified as BORIS-
low expressing tumor cells.
Hoechst side population (SP) analysis is a proven technique to enrich stem and early pro-
genitor cells in different cell lines [13–15]. Fluorescence imaging analysis was performed using
Hoechst 33342 in combination with BORISmRNA detection using BORIS-Molecular Beacon
(BORIS-MB), as previously described [25]. Fluorescence imaging analyses showed that the
BORIS/CTCFL in Human Cancer Stem Cells
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BORIS positive cells are only a subset of cells in all analyzed epithelial tumor cell lines (Fig 1B),
consistent with results obtained in embryonic tumor cells [25]. The estimated frequency of
BORIS positive cells is approximately 0.1% in HeLa, 0.5% in HT29 and less than 0.05% in
MCF7 and MDA-MBA-231 cells; in contrast it was about 5% in NCCIT [25]. Interestingly,
Fig 1. BORIS expression and SP analysis in human epithelial tumor cell lines. (A) BORIS expression in
human tumor cell lines. Total RNA from NCCIT (embryonic), HeLa (cervical), HT29 (colon), MCF7 (non-
invasive breast) and MDA-MB-231 (invasive breast) tumor cells were extracted and BORIS expression was
analyzed by qRT-PCR. The results were normalized toGAPDH and related to NCCIT cells. Error bars
represent the mean ± SD (n = 3). (B) BORIS expression as detected using BORIS-MB. Representative
images of HeLa, HT29, MCF7 and MB-MDA 231 cells, 40X magnification. Cells were incubated with
Cy3-BORIS MB (200 nM) and Hoechst 33342 (5 μg/mL) at 37°C for 1.5 hour in serum-free medium and then
examined under fluorescent microscopy. White arrows indicate Hoechst negative cells which are also BORIS
mRNA positive as detected by BORIS-MB.
doi:10.1371/journal.pone.0132977.g001
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fluorescence imaging analyses showed that the majority of BORIS positive cells were also
Hoechst negative (white arrows in Fig 1B and S1 Fig). Therefore, BORIS expression could be
associated with Hoechst negative phenotype of SP cells in cervical, colon and breast tumor
cells. However, a small percentage (less than 10%) of BORIS positive cells were Hoechst
positive.
ABCG2 is described as the major efflux pump responsible for Hoechst negative phenotype
in SP cells [27]. Hence, a possible co-expression of BORIS with the chemoresistance transporter
protein ABCG2, was first investigated. HeLa cells were used in this experiment. As can be
seen in Fig 2A, BORIS positive cells are both negative for Hoechst (white arrows) and positive
for ABCG2 protein. To confirm the presence of BORISmRNA in CSC-enriched population of
HeLa cells, the SP cells and also the non-SP (NSP) cells were sorted by FACS. The percentage
of SP cells was from 0.5% to 1.5% of the total cells (Fig 2B), consistent with previous reports
[15, 27]. The SP fraction was completely reduced by adding verapamil, an inhibitor of the
ABC-transporters, indicating that the population was bona fide SP cells. The qRT-PCR analysis
showed that BORISmRNA level of SP cells was significantly higher (12 fold, p<0.05) com-
pared to NSP and parental HeLa cells (Fig 2C). Also the ABCG2mRNA level was higher
(about 1.5 fold) in SP sorted cells compared to NSP and parental cells (Fig 2D). To further ver-
ify the presence of BORIS in the SP CSC-enriched population, the frequency of SP was analyzed
in pCMVBORIS-transfected HeLa cells (Fig 2E). As expected, the overexpressing BORIS cells
were significantly more enriched in SP cells (2 fold, p = 0.01) compared to HeLa parental cells.
All these results indicated that the isolation of BORIS-positive cells could lead to an enrichment
of the CSC population in HeLa tumor cells.
Colon-spheres and mammo-spheres express high levels of BORIS
mRNA
The growth of cells in suspension, with a serum-free medium (sphere culture), is a common
approach to CSC-enrichment [7–8]. As this property was reported to be restricted to stem/
progenitor cells [19], BORIS expression was also investigated in forming-spheres of colon
(HT29) and breast (MCF7) tumor cells. An aliquot of spheres were seeded in serum-containing
medium to allow the differentiation. Interestingly, BORIS expression analysis revealed a signifi-
cant higher level of BORISmRNA in colon-spheres (37.2 ± 7.3 fold, n = 4) as well as in
mammo-spheres (30.9 ± 6.4 fold, n = 4), compared to parental cells and differentiated-spheres
(Fig 3). These results suggested that BORIS is expressed in the CSC-enriched spheres of colon
and breast tumor cells.
Gene expression and CSC phenotype in BORIS knockdown cells
To explore a possible role of BORIS in CSCs, we selected a knockdown strategy using lentiviral
system with inducible expressing shRNAs targeting human BORISmRNA. The BORIS sh-3,
BORIS sh-4 and scrambled-shRNA (CTR sh) lentiviruses were previously generated and vali-
dated [25]. These lentiviruses were used to infect HeLa, HT29, MCF7 and MBA-MD-231
tumor cells.
It has been demonstrated that BORIS activates hTERT expression [28] and affects the
expression of stemness genes in embryonic tumor cells [25]. In this study, these correlations
were explored in epithelial tumor cells. After 2 weeks of BORIS knockdown, expression analy-
ses of hTERT, CTCF, the most common CSC markers (ABCG2, CD44, ALDH1) and stem cell
(NANOG, OCT4, SOX2, BMI1) genes were performed. Fig 4A shows, for all analyzed genes, the
mean of the fold change of BORIS sh-3 and BORIS sh-4 cells compared to CTR sh cells of each
engineered tumor cell line. hTERT expression was significantly down-regulated in all analyzed
BORIS/CTCFL in Human Cancer Stem Cells
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tumor cells at the exception of MCF7, in which a significant up-regulation (13 fold) was
observed. CTCF expression was decreased in all cells, even if the decrease was not significant
Fig 2. BORIS and ABCG2 expression in isolated SP HeLa cells. (A) Immunofluorescence analysis of ABCG2 in HeLa cells. The cells were incubated with
BORIS-MB and Hoechst 33342 at 37°C for 1.5 h in serum-free medium. After cytocentrifugation the slides were fixed with cold acetone and then incubated
with rabbit polyclonal ABCG2 antibody. The BORIS positive/ABCG2 positive/Hoechst negative cells are indicated with white arrows. 10X magnification. (B)
Representative dot plot of flow cytometry analysis of SP. HeLa cells were incubated with Hoechst 33342 (12.5 μg/mL) either alone or in combination with
verapamil (50 μM). The analysis was performed using LSRII and the sorting using FACS Aria. The gates indicate the sorted SP and NSP cells. (C) BORIS
mRNA and (D) ABCG2mRNA expression in SP and NSP isolated from HeLa cells. Total RNA was extracted and analyzed by qRT-PCR. Graphs indicate the
mRNA levels of BORIS and ABCG2 genes normalized toGAPDH and related to the parental HeLa cells. Data are represented as mean ± SD from 3
independent experiments. Asterisk indicates p<0.05. (E) SP analysis in BORIS overexpressed cells. HeLa cells were transiently transfected with a BORIS
expression vector (HeLa pCMVBORIS). After 2 days, 1 x 106 cells were incubated with Hoechst 33342 (12.5 μg/mL) either alone (top) or in combination
(bottom) with 50 μM verapamil. The analysis was performed using LSRII flow cytometry and one representative experiment of 3 independent experiments is
shown.
doi:10.1371/journal.pone.0132977.g002
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(from 40% to 20% compared to control). Notably, absence of BORIS trigged a decrease of the
ABCG2 expression (93% for MCF7, 25% for MDA-MB-231, 80% for HT29 and 60% for HeLa).
CD44 was down-regulated in all but one cell line, MCF7, in which a 2.5 fold increase was
observed. ALDH1, NANOG, OCT4, SOX2 and BMI1 were generally down-regulated in all
tumor cells after BORIS silencing. All together, these results suggested that BORIS could signif-
icantly affect the regulation of hTERT/telomerase, stem cell and CSC marker genes in epithelial
tumor cells.
CD44+/CD24- subpopulation has been found to be enriched with tumor-initiating features,
especially in breast cancer cells [6, 29]. In this study, CSC subpopulation was analyzed by flow
cytometry in BORIS-knockdown tumor cells. A different behavior of MCF7 compared to the
other cells was observed (Fig 4B). The analyses revealed a remarkable acquisition of CD44
+/CD24- phenotype in BORIS-knockdown MCF7-derived cells, from none CD44+/CD24-
cells in the control to about 70% in the BORIS-knockdown cells. A non significant decrease of
CD44+/CD24- subpopulation was observed in BORIS-shRNAMDA-MB-231-derived cells. In
the non-breast tumor cells, HT29 and HeLa, no change of expression was observed with both
cells displaying a typical CD44+/CD24- epithelial phenotype.
Knockdown of BORIS affects cell proliferation in MCF7 breast cells
Cell survival was assessed following BORIS knockdown. Cell proliferation and the capacity
to form colonies were measured each week for one month. The colony formation (or clono-
genic) assay monitors the ability of a cancer cells to produce a viable colony after treatment
[30] and was used to analyze the in vitro capacity of tumor cells to form colonies after BORIS
Fig 3. BORIS expression in colon-spheres andmammo-spheres. Cells were seeded at low density
(1,000 cells/ml) in sphere culture medium in low attachment plates. After 10–15 days spheres were collected
for RNA extraction and an aliquot of spheres was seeded in normal medium with serum to allow the
differentiation (differentiated-spheres). BORIS expression was analyzed by qRT PCR in (A) colon-spheres
(HT29 spheres) and differentiated-spheres (HT29 DIFF spheres) and in (B) mammo-spheres (MCF7
spheres) and differentiated-spheres (MCF7 DIFF spheres). Data were normalized toGAPDH and related to
parental cells (cells). One representative experiment of 4 independent experiments is shown. Asterisks
indicate statistically significant difference (p<0.05) between spheres and parental cells. (C) Representative
images of colon-spheres and mammo-spheres are shown, 4X magnification. Black scale bars indicate
250 μm.
doi:10.1371/journal.pone.0132977.g003
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knockdown. Results showed no significant difference on cell proliferation in all but one
tumor cell line. The exception concerned MCF7 cells in which a significant increase (3–4 fold,
p<0.0001) of cell proliferation compared to control cells was observed (Fig 5A). Colony
formation assays confirmed the cell proliferation results (Fig 5B). After one month of BORIS-
knockdown, the numbers of colonies were not significantly different for HeLa, HT29 and
MDA-MB-231, compared to controls. In contrast, the number of colonies was significantly
higher in MCF7. These results indicated that, at the exception of MCF7 breast cancer cells,
BORIS silencing in epithelial tumor cells did not have a significant impact on cell survival.
Knockdown of BORIS impairs the sphere formation capacity of colon
and breast tumor cells
The impact of BORIS knockdown on self-renewal capacity of tumor spheres was also consid-
ered. Notably, the total number of tumor spheres was significantly decreased in all BORIS-
shRNA derived cells (Fig 6). The number of spheres formed by BORIS-shRNA engineered
Fig 4. Impact of BORIS-knockdown on gene expression and CSC profile. (A) MCF7, MDA-MB-231, HT29 and HeLa cells were engineered to stably
exhibit knocked-down BORISmRNA. BORIS sh-3, sh-4 and CTR sh (control shRNA containing scrambled sequence) lentiviruses were used to infect these
cells. Each transduced cells were cultured with doxycycline to induce BORIS shRNA expression. Medium containing doxycycline was replaced every 3 days.
After 2 weeks, RNA was isolated from BORIS sh-3, sh-4 and CTR sh of each transduced cell line. mRNA levels of the indicated genes were analyzed by
qRT-PCR. Graphs represent for each gene the means of fold induction of both BORIS shRNA (BORIS sh-3 and sh-4) related to that of control of any cells.
Standard errors were calculated considering error propagation of both BORIS shRNA analyses. Graphs show one representative experiment. (B)
Representative flow cytometry dot plots of CD44 and CD24 expression in MCF7, MDA-MB-231, HT29 and HeLa cells engineered to stably exhibit knocked-
down BORISmRNA. CD44 and CD24 expression patterns of the two BORIS shRNA (BORIS sh-3 and sh-4) and the control (CTR sh) are shown. Anti-CD24
antibody labeled with AlexaFluor 647 and anti-CD44 antibody labeled with APC-H7 were used. The percentage of CD44+/CD24- population was estimated
after gating on eGFP and tRFP positive cells (transduced and dox-induced shRNA, respectively) and the final gates are based on the isotype control
corresponding to each cell line. All experiments were conducted independently three times and one representative experiment is shown for each group of
cells.
doi:10.1371/journal.pone.0132977.g004
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derived cells was significantly decreased compared to control (90–95% for MCF7, 30–40% for
MDA-MB-231 and 60% for HT29). Representative images of spheres show that the size was
similar between BORIS-sh and CTR sh derived spheres for MDA-MB-231 and HT29 (Fig 6B
and 6C, right). However, the size of spheres of BORIS-shRNAMCF7-derived cells were larger
compared to control cells (Fig 6A, right), the sphere diameters were 400 μm and 200 μm,
respectively. Interestingly, it emerged that BORIS depletion had a negative effect on tumor
sphere formation capacity in colon and in breast cancer cells in which the number of spheres
were dramatically reduced. This result indicated that BORIS could play a role in the self-
renewal capacity of colon and breast cancer cells.
Gene expression profile analysis was also investigated in formed spheres after BORIS silenc-
ing. The spheres formed by HT29 and MDA-MB-231 BORIS-depleted cells showed a down-
regulation (15–20%) of hTERT expression compared to controls (Fig 6D). In contrast, BORIS
depleted-MCF7 spheres displayed a strongly increase of hTERT expression (11 fold). No signif-
icant difference was observed for CTCF in the different tumor cell lines. These observations
Fig 5. Impact of BORIS knockdown on cell survival in epithelial tumor cells. (A) Cell proliferation, over 1
month of dox-induced BORIS- and CTR- shRNA cells, was analyzed each week by MTT assay. Results of the
two specific BORIS-shRNA (BORIS sh-3 and sh-4) are indicated as a percentage compared to the cell
proliferation of control cells (scrambled shRNA, CTR sh). Error bars represent the mean ± SD (n = 3). Asterisks
indicate statistically significant difference (p<0.05) between BORIS sh and CTR sh. (B) Representative images
of colony formation assay after 1 month of BORIS knockdown. Three hundred cells were seeded in each well of
6-well plates with medium containing doxycycline, each cell group were prepared in triplicate. Cells were
cultured for 2 weeks, then were fixed and stained with crystal violet.
doi:10.1371/journal.pone.0132977.g005
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were consistent with the findings already observed in BORIS knockdown cells (Fig 4A).
The expression profile of stem cell and CSC markers genes of BORIS-depleted spheres showed
that NANOG, OCT4 and SOX2 genes were down-regulated in both breast and colon tumor
cells. ABCG2 expression was decreased for all BORIS-silenced spheres. CD44 and ALDH1
were up-regulated in BORIS-depleted spheres of breast tumor cells (3.7 for MCF7, 1.5 fold for
MDA-MB-231) but down-regulated in HT29 BORIS-depleted spheres. All these results dem-
onstrated that the phenotype could be dependent of the origin of the tumor cells.
Fig 6. Knockdown of BORIS reduces the ability to form spheres and down-regulates the expression
of stem cell genes. (A) MCF7, (B) MDA-MB-231 and (C) HT29 cells were engineered to stably exhibit
knocked-down BORISmRNA. After 2 weeks of dox-induction of BORIS- and CTR- shRNA cells were seeded
at low density (1000 cells/ml) in sphere serum-free medium into ultra-low attachment 6-well plates in
triplicates. Doxycycline was added every 3 days to maintain shRNA induction. Formed spheres were counted
after 10 days. Error bars represent the mean ± SD (n = 3). One asterisk (p<0.05) or two asterisks (p<0.001)
indicate statistically significant difference between BORIS sh and CTR sh spheres. On the right are shown
representative images of spheres. MCF7-spheres and HT29-spheres, 4X magnification. MDA-MB-
231-spheres, 10X magnification. Black scale bars indicate 250 μm. (D) Expression analysis of BORIS-
depleted spheres. Total RNA was isolated from BORIS sh-3, sh-4 and CTR sh formed spheres. mRNA levels
of the indicated genes were analyzed by qRT-PCR. Graphs represent for each gene the means of fold
induction of both BORIS shRNA (BORIS sh-3 and sh-4) related to that of control. Standard errors were
calculated considering error propagation of both BORIS shRNA analyses. Graphs show one representative
experiment.
doi:10.1371/journal.pone.0132977.g006
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Knockdown of BORIS up-regulates epithelial-mesenchymal-transition
(EMT)-related genes in MCF7 cells
In BORIS-depleted MCF7 cells, we observed an increase of hTERT transcription, an acquisition
of the CSC phenotype (CD44+/CD24-) and an increase of cell survival. Interestingly, a change
in morphology was also noticed (Fig 7A). These cells formed structures with irregular shape
and unique spindle morphology. This particular morphology is characteristic of mesenchymal
cells, such as MDA-MB-231 cells (Fig 7A), thus we further investigated whether an alteration
of the genes controlling the epithelial–mesenchymal transition (EMT) cellular process could
occur in MCF7 cells. Expression of a panel of representative genes, which act during the EMT
program, were analyzed by qRT-PCR after BORIS silencing (Fig 7B). Interestingly, it emerged
that BORIS-depleted MCF7 cells acquired EMT gene signature. As expected, the mesenchymal
MDA-MB-231 cells neither changed of morphology (Fig 7A) nor modified significantly EMT
gene expression profile (Fig 7B). In contrast, MCF7 cells after BORIS silencing lost the expres-
sion of epithelial markers, such as cytokeratin-19 (CK19), epithelial cellular adhesion molecule
(EpCAM) and especially E-cadherin (ECADH). Simultaneously, we observed a remarkable up-
regulation of several mesenchymal markers, including SNAI1 (SNAIL), Twist-related protein 1
(TWIST) and vimentin (43, 238 and 3567 fold increase, respectively). No significant change in
expression was noticed in the other EMT-related genes, SNAI2 (SLUG), N-cadherin and fibro-
nectin. All these results suggested that BORIS could affect the EMT process in luminal-like
non-invasive breast cancer cells and indicated that BORIS may regulate some of the EMT-
related genes, such as CDH1 (ECADH), SNAIL, TWIST and VIMENTIN. To confirm the acqui-
sition of EMT phenotype of MCF7 cells after BORIS knockdown, we analyzed the migration
Fig 7. Acquisition of EMT phenotype and gene signature of MCF7 cells after BORIS silencing. (A) Representative images of MCF7- and MDA-MB-231-
derived cells after dox-induction of BORIS- and CTR- shRNA, 10X magnification. Black scale bars indicate 250 μm. (B) After 2 weeks of BORIS knockdown,
mRNA levels of the indicated genes were analyzed by qRT-PCR. Graphs represent for each gene the means of fold induction of both BORIS shRNA (BORIS
sh-3 and sh-4) related to the control. Standard errors were calculated considering error propagation of both BORIS shRNA. Graphs show one representative
experiment. Results are shown in logarithmic scale. (C) Cell migration assay of MCF7 cells after BORIS knockdown. Graph shows the mean of cell number
visualized in 10 different fields ± SD (n = 3). One asterisk (p<0.05) or two asterisks (p<0.001) indicate statistically significant difference between BORIS sh
and CTR sh. On the right, representative images, 10X magnification.
doi:10.1371/journal.pone.0132977.g007
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capacity of these cells. As expected, the non-invasive breast MCF7 cells, which normally do not
migrate, acquired the capacity to migrate after BORIS silencing (Fig 7C). This last finding con-
firmed the acquisition of EMT gene signature of MCF7 cells after BORIS silencing.
Cell viability in BORIS knockdown-derived cells after 5-FU treatment
The chemoresistance is a characteristic feature of CSCs [3] and it was reported that an increase
of hTERT, EMT genes and CD44+/CD24- expression allow to an enhancement of resistance to
chemotherapeutic drugs [31–33]. In BORIS inhibition experiments, an increase of hTERT,
EMT genes expression and an acquisition of CD44+/CD24- phenotype were seen in MCF7
cells. To better analyze the effects of BORIS silencing in the analyzed epithelial tumor cells, the
impact of treatment with a chemotherapeutic drug was also analyzed. The 5-Fluorouracil
(5-FU) is one of the most used drugs in chemotherapy. This drug is used to treat several can-
cers including colon, breast, ovarian, head and neck and liver cancer [34].
After 2 weeks of BORIS silencing, the derived tumor cells were treated with different con-
centration of 5-FU (0.5, 5, 50 and 500 μg/ml). The cell viability was determined by MTT assay
and was expressed as the percentage of surviving 5-FU-treated cells compared to non-treated
cells (Fig 8). As expected, BORIS-depleted MCF7 cells were significantly (p<0.01) more resis-
tant to 5-FU compared to the control cells. BORIS-depleted MDA-MB-231 cells acquired che-
moresistance only at low concentrations (0.5 and 5 μg/ml) of 5-FU. For HT29 and HeLa cells
the treatment with 5-FU did not change the cell viability of the BORIS-depleted cells.
The effects of induction of BORIS expression on cell growth and hTERT
expression
In order to further investigate the biological effects of BORIS in epithelial tumor cells, we gen-
erated stable cells in which BORIS cDNA was expressed under the control of doxycycline.
Interestingly, at the exception of HT29, the analysis of cell proliferation showed a significant
decrease of cell growth after BORIS-induction (Fig 9A). The inhibition of cell proliferation was
dramatically affected in MCF7 cells, already after 5 days of BORIS induction. These results
were in agreement with the analysis of colony formation (Fig 9B), which demonstrated a signif-
icant decrease of clonogenic cell potential. These data suggested a role of BORIS in tumor cell
proliferation as a tumor suppressor gene in cervical and breast tumor cells.
Cell morphology was not modified after BORIS induction (data not shown). The analysis of
expression profile, 10 days after BORIS induction, showed that hTERT expression was signifi-
cantly increased in MDA-MB-231, HT29 and HeLa cells (8.7, 3.3 and 4.8 fold, respectively)
(Fig 9C). In contrast, a decrease of hTERT expression was observed in MCF7 cells. These find-
ings are in correlation with the data found in BORIS-depleted cells in which hTERT expression
was changed in opposite manner. No significant change of expression was found for CTCF,
ABCG2 and CD44. For ALDH1 and stem cell genes, a cell-dependent behavior was observed.
Indeed, for certain cells, a significant up-regulation was noticed for SOX2 and NANOG. The
analysis of CD44+/CD24- expression profile showed that BORIS-induced cells did not have a
different phenotype compared to control cells (data not shown).
All these data further confirmed that BORIS could play an important role in the regulation
of hTERT expression and stem cell genes but in a cell-type dependent manner.
Discussion
Our data demonstrated that BORIS-positive cells are only a small subpopulation (0.02–
0.5%) and this cell subset could be CSC-enriched. Furthermore, high BORIS expression was
found in the CSC-enriched populations isolated from HeLa SP cells, colon-spheres and
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mammo-spheres. These observations are consistent with recent reports showing a correlation
between BORIS expression and advanced stage in different cancers [21–24]. In hepatocellular
carcinoma tissues, a correlation between BORIS expression and the CSC marker CD90 has also
been observed [24].
The potential role of BORIS in CSCs may arise from the functional studies conducted in
this study. Analysis of gene expression profiles after BORIS silencing revealed significant
down-regulation of hTERT, stem cell and CSC marker genes in the analyzed cells and also in
derived spheres. These results, in accordance with our previous study in embryonic cancer cells
[25], demonstrate that BORIS can regulate the expression of hTERT, stem cell and CSC marker
genes not only in embryonic cancer but also in epithelial tumor cells. This role of BORIS could
explain the significant reduction of the capacity to form spheres in colon and breast tumor
cells, indicating a putative involvement of BORIS in the self-renewal of tumor cells. Neverthe-
less, BORIS silencing did not lead to a significant inhibition of cell proliferation, even after a
relatively long time of BORIS silencing (2 months, data not shown). This result could be
explained by the fact that the analyzed tumor cells are BORIS-low expressing cell lines. Hence,
an inhibition of BORIS in a small subpopulation of BORIS positive cells would take long time
to have a significant impact on cell proliferation of the entire bulk of tumor cells. The discrep-
ancy with the significant reduction of spheres could be due to the different conditions in which
Fig 8. Effect of 5-FU on cell proliferation of BORIS-depleted tumor cell lines. After 2 weeks of BORIS
knockdown cells were seeded (1 x 104 cells/well) in 96-well plates in doxycycline-containing medium. The
day after was added 5-FU at different concentrations: 0.5, 5, 50 and 500 μg/ml. Cells were incubated for 2
days and then cell viability was measured by MTT assay. The percentage of viable cells (% of surviving
fraction) is shown relative to that of the untreated control. Error bars represent the mean ± SD (n = 3). One
asterisk (p<0.05) or two asterisks (p<0.01) indicate statistically significant difference between BORIS sh and
CTR sh cells.
doi:10.1371/journal.pone.0132977.g008
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the analyses were done. Indeed, the cell viability analyses were measured at steady state and
included all the bulk tumor cells, while the sphere cultures create experimental conditions that
are favorable to stem cells.
Our results are apparently inconsistent with a previous work which has shown an increase
of apoptosis after BORIS-knockdown in MDA-MB-231 cells [35]. This difference could be due
to the different experimental conditions and settings. In our study, the experiments have been
designed to minimize the risk of false or ambiguous results. For each cell line, we generated
two different stable BORIS-depleted cells, and the analyses were performed after 2 weeks of
BORIS silencing. Notably, all the assays were executed with FACS-isolated transduced cells.
Furthermore, the selected BORIS shRNAs do not overlap with the homolog sequences of
CTCF and target the exon 9, which is present in almost all the BORISmRNA isoforms [36].
A completely different phenotype, after BORIS knockdown, was observed in the non-inva-
sive MCF7 breast tumor cells. We observed a remarkable different morphology in both two sta-
ble BORIS-shRNA engineered MCF7-derived cells compared to control cells and a significant
enhancement of cell proliferation. The gene expression profile analysis revealed a notable up-
regulation of hTERT, CD44 and ALDH1 genes. Importantly, an acquisition of the CSCs pheno-
type (CD44+/CD24-) and an increase of chemoresistance after 5-FU treatment were observed.
Fig 9. Inhibition of cell growth and up-regulation of hTERT and stem cell genes expression, after
BORIS-induction in epithelial cancer cells.MCF7, MDA-MB-231, HT29 and HeLa cells were engineered
to stably express BORIS cDNA. After transduction with either lentivirus harboring BORIS cDNA (BORIS) or
control lentivirus (CTR), cells were selected by incubation with the antibiotic G418 for at least 2 weeks. (A)
Cell proliferation was analyzed by MTT assay after 5 and 10 days of dox-induction of BORIS expression.
Results are indicated as a percentage compared to the control cells (CTR). Error bars represent the
mean ± SD (n = 3). One asterisk (p<0.05) or two asterisks (p<0.01) indicate statistically significant difference
between BORIS and CTR cells. (B) Representative images of colony formation assay. Three hundred cells
were seeded in each well of 6-well plates with medium containing doxycycline, each assay was performed in
triplicate. Cells were cultured for 2 weeks, then were fixed and stained with crystal violet. (C) After 2 weeks of
dox-induction of BORIS and CTR cells, mRNA levels of the indicated genes were analyzed by qRT-PCR.
Graph represents for each gene the fold induction of BORIS-induced cells related to control cells. Error bars
represent the mean ± SD (n = 3).
doi:10.1371/journal.pone.0132977.g009
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Although, a decrease of sphere formation capacity was observed, the size of spheres was larger
compared to those of control and this observation can be correlated with the morphologic
modification of the MCF7 cells after BORIS silencing. Since a morphologic change to a mesen-
chymal phenotype was detected in MCF7 cells, we further explored the change of expression of
genes involved in the EMT program. A significant up-regulation of the most important mesen-
chymal marker genes (SNAIL, TWIST and VIMENTIN) and a down-regulation of epithelial
genes (E-cadherin, Cytokeratin-19 and EpCAM) were observed. The increase of migration
capacity confirmed the acquisition of EMT signature. Interestingly, a remarkable increase of
hTERT expression was also observed in BORIS-depleted MCF7cells. This up-regulation of
hTERT could be an explanation for the phenotype modification observed in MCF7 cells.
Indeed, it has been demonstrated that hTERT/telomerase has also telomere-independent func-
tions [37] and an overexpression of hTERT led cells more resistant to several insults, such as
treatment with chemotherapeutic [31–32]. An increase of chemoresistance was detected in
BORIS-depleted MCF7cells. An enhancement of cell proliferation was also observed, which is
in accordance to previous reports in which hTERT was ectopically expressed [28, 38, 39].
Recent studies have shown that hTERT can also act as a transcriptional modulator of the Wnt/
β-catenin signaling pathway [40–41] which is able to regulate the EMT program. As well, Wnt
signaling aberrantly drives EMT genes to tumor formation in experimental models [42]. Cells
that undergo the EMT process acquire the CD44+/CD24- expression pattern and the ability to
form spheres [33]. Indeed, an acquisition of CSCs phenotype and the ability to form bigger
spheres were found in BORIS-depleted MCF7 derived cells. Further studies analyzing the
tumorigenic potential of these derived BORIS-depleted MCF7 spheres may highlight their bio-
logical functions. Additionally, we observed a significant down-regulation of CDH1 (E-cad-
herin) gene. The adhesive glycoprotein E-cadherin is the master-regulator of the epithelial
phenotype and its loss is considered a hallmark of EMT. CDH1 has been shown transcription-
ally silenced by its transcriptional repressors, including SNAI1 (SNAIL), SNAI2 (SLUG) and
TWIST [43]. Another important marker of EMT, which was up-regulated in BORIS-depleted
MCF7 cells, is VIMENTIN, a major constituent of the intermediate filament family of proteins.
VIMENTIN is ubiquitously expressed in normal mesenchymal cells and its overexpression is
frequently associated with increased migratory and invasive capacity of cancer cells [44]. In
BORIS-depleted MCF7 cells, an increase of migration capacity was indeed observed and this
result could be associated with the up-regulation of VIMENTIN. In summary, all these data
suggest that BORIS could mediate the regulation of EMT process by transcriptional regulation
of hTERT and EMT target genes in the non-invasive MCF7 breast tumor cells. More investiga-
tions are required to better define the role of BORIS in the EMT process.
The gene expression profiles can give an explanation about the different phenotypes found
in the analyzed epithelial tumor cells after BORIS knockdown. Notably, different phenotypes
were observed in the two analyzed breast tumor cell lines. MCF7 cells are luminal-like, weakly
proliferative and non-invasive, they display epithelial phenotypic markers and express the
nuclear hormone receptor (ERα). Instead, MDA-MB-231 cells are basal-like, invasive with
ability to migrate, display a mesenchymal phenotype and are ERα-negative. These cell lines are
phenotypically and genetically different; therefore, BORIS could affect target genes that are dif-
ferentially expressed in these cell lines. In addition, MCF7 cells have a different BORIS pro-
moter usage compared to the other analyzed cells. BORIS is transcriptionally controlled by
three alternative promoters [45]. The promoters A and C are equally active in MCF7, whereas
in the majority of tumor cell lines, BORIS is transcriptionally regulated by the promoter C
only. Therefore, in MCF7 and MDA-MB-231, different BORIS proteins could be expressed
with potentially diverse biological functions.
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To further investigate the biological functions of BORIS in cancer, we induced BORIS
expression in BORIS-low expressing epithelial tumor cells. Our observations in MCF7,
MDA-MB-231 and HeLa were consistent with those of recent reports in which BORIS overex-
pression inhibits cell growth [46–48]. Contradictory results showed the relation to the cell
cycle progression in BORIS-overexpressing cells. One study demonstrated that BORIS induc-
tion did not alter the cell cycle profile of both normal and cancer cell lines [48]. Another study
reported that BORIS overexpression in normal HEK293 cells led to an accumulation of cells in
S phase, an increase of cell size and a decrease of the cell cycle markers PCNA and Cyclin A
[47]. In our experiments, no change of cell size was observed by flow cytometry analysis after
BORIS-induction (data not shown). Gene expression profiles showed that BORIS induction
promoted hTERT expression in MDA-MB-231, HT29 and HeLa cells. These results are in
agreement with our previous studies [25, 28]. All together these data further support the evi-
dence that BORIS regulates the hTERT gene at the transcriptional level.
The results here presented open new findings to better understand the role of BORIS in
tumor development and provide the evidence for a potential new CSC biomarker that could be
used as therapeutic target for cancer therapy.
Supporting Information
S1 Table. Primer sequences for qRT-PCR analysis.
(PDF)
S1 Fig. BORIS expression and SP analysis. Representative images of HeLa and HT29 cells
after incubation of BORIS-MB and Hoechst 33342. Cells were examined under confocal
microscopy, 63X magnification.
(TIFF)
Acknowledgments
We thank Dr. Sonia Chelbi for helpful advice and discussion. Also, we thank the flow cytome-
try facility of EPFL for their assistance.
Author Contributions
Conceived and designed the experiments: LA JB. Performed the experiments: LA. Analyzed the
data: LA SL JB. Contributed reagents/materials/analysis tools: LA LL JB. Wrote the paper: LA
JB.
References
1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature.
2001 Nov 1; 414(6859):105–11. PMID: 11689955
2. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annual review of medicine.
2007; 58:267–84. PMID: 17002552
3. Jordan CT, GuzmanML, Noble M. Cancer stem cells. The New England journal of medicine. 2006 Sep
21; 355(12):1253–61. PMID: 16990388
4. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. BioEssays: news
and reviews in molecular, cellular and developmental biology. 2009 Oct; 31(10):1038–49.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nature medicine. 1997 Jul; 3(7):730–7. PMID: 9212098
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumor-
igenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of
America. 2003 Apr 1; 100(7):3983–8. PMID: 12629218
BORIS/CTCFL in Human Cancer Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0132977 July 17, 2015 18 / 21
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour
initiating cells. Nature. 2004 Nov 18; 432(7015):396–401. PMID: 15549107
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expan-
sion of human colon-cancer-initiating cells. Nature. 2007 Jan 4; 445(7123):111–5. PMID: 17122771
9. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colo-
rectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of
America. 2007 Jun 12; 104(24):10158–63. PMID: 17548814
10. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem
cells. Cancer research. 2007 Feb 1; 67(3):1030–7. PMID: 17283135
11. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of
ovarian cancer-initiating cells from primary human tumors. Cancer research. 2008 Jun 1; 68(11):4311–
20. doi: 10.1158/0008-5472.CAN-08-0364 PMID: 18519691
12. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges
and opportunities for anticancer drug discovery. Nature reviews Drug discovery. 2009 Oct; 8(10):806–
23. doi: 10.1038/nrd2137 PMID: 19794444
13. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side popula-
tion" of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy
of Sciences of the United States of America. 2004 Sep 28; 101(39):14228–33. PMID: 15381773
14. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepa-
tocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006 Jul; 44(1):240–
51. PMID: 16799977
15. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6
glioma cell line. Proceedings of the National Academy of Sciences of the United States of America.
2004 Jan 20; 101(3):781–6. PMID: 14711994
16. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines
contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer
research. 2009 Feb 15; 69(4):1302–13. doi: 10.1158/0008-5472.CAN-08-2741 PMID: 19190339
17. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of
normal and malignant humanmammary stem cells and a predictor of poor clinical outcome. Cell stem
cell. 2007 Nov; 1(5):555–67. doi: 10.1016/j.stem.2007.08.014 PMID: 18371393
18. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblasto-
mas cultured in bFGF and EGFmore closely mirror the phenotype and genotype of primary tumors
than do serum-cultured cell lines. Cancer cell. 2006 May; 9(5):391–403. PMID: 16697959
19. Dontu G, AbdallahWM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation
and transcriptional profiling of humanmammary stem/progenitor cells. Genes & development. 2003
May 15; 17(10):1253–70.
20. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, et al. BORIS, a novel male
germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-
finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Pro-
ceedings of the National Academy of Sciences of the United States of America. 2002 May 14; 99
(10):6806–11. PMID: 12011441
21. Woloszynska-Read A, ZhangW, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, et al. Coordinated
cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with
the BORIS/CTCF expression ratio and advanced stage. Clin Canc Res. 2011 Apr 15; 17(8):2170–80.
22. Cheema Z, Hari-Gupta Y, Kita GX, Farrar D, Seddon I, Corr J, et al. Expression of the cancer-testis anti-
gen BORIS correlates with prostate cancer. Prostate. 2014 Feb; 74(2):164–76. doi: 10.1002/pros.
22738 PMID: 24123052
23. Okabayashi K, Fujita T, Miyazaki J, Okada T, Iwata T, Hirao N, et al. Cancer-testis antigen BORIS is a
novel prognostic marker for patients with esophageal cancer. Cancer science. 2012 Sep; 103(9):1617–
24. doi: 10.1111/j.1349-7006.2012.02355.x PMID: 22676270
24. Chen K, HuangW, Huang B, Wei Y, Li B, Ge Y, et al. BORIS, brother of the regulator of imprinted sites,
is aberrantly expressed in hepatocellular carcinoma. Genetic testing and molecular biomarkers. 2013
Feb; 17(2):160–5. doi: 10.1089/gtmb.2012.0242 PMID: 23237599
25. Alberti L, Renaud S, Losi L, Leyvraz S, Benhattar J. High expression of hTERT and stemness genes in
BORIS/CTCFL positive cells isolated from embryonic cancer cells. PloS one. 2014; 9(10):e109921.
doi: 10.1371/journal.pone.0109921 PMID: 25279549
26. Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, et al. The pINDUCER lentiviral toolkit for
inducible RNA interference in vitro and in vivo. Proceedings of the National Academy of Sciences of the
BORIS/CTCFL in Human Cancer Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0132977 July 17, 2015 19 / 21
United States of America. 2011 Mar 1; 108(9):3665–70. doi: 10.1073/pnas.1019736108 PMID:
21307310
27. Katayama R, Koike S, Sato S, Sugimoto Y, Tsuruo T, Fujita N. Dofequidar fumarate sensitizes cancer
stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug
export. Cancer science. 2009 Nov; 100(11):2060–8. doi: 10.1111/j.1349-7006.2009.01288.x PMID:
19673889
28. Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, et al. BORIS/CTCFL-mediated
transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic
acids research. 2011 Feb; 39(3):862–73. doi: 10.1093/nar/gkq827 PMID: 20876690
29. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24-
breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.
Breast cancer research: BCR. 2006; 8(5):R59. PMID: 17062128
30. Puck TT, Marcus PI. Action of x-rays on mammalian cells. The Journal of experimental medicine. 1956
May 1; 103(5):653–66. PMID: 13319584
31. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Segal-Bendirdjian E. Death receptor signaling
regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telo-
mere maintenance. Oncogene. 2004 Sep 30; 23(45):7469–74. PMID: 15326479
32. Luiten RM, Pene J, Yssel H, Spits H. Ectopic hTERT expression extends the life span of human CD4+
helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis.
Blood. 2003 Jun 1; 101(11):4512–9. PMID: 12586632
33. Mani SA, GuoW, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transi-
tion generates cells with properties of stem cells. Cell. 2008 May 16; 133(4):704–15. doi: 10.1016/j.cell.
2008.03.027 PMID: 18485877
34. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant
therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 ran-
domized trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.
2009 Feb 20; 27(6):872–7.
35. Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, et al. Selective apoptosis of breast
cancer cells by siRNA targeting of BORIS. Biochemical and biophysical research communications.
2008 May 23; 370(1):109–12. doi: 10.1016/j.bbrc.2008.03.040 PMID: 18355444
36. Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, et al. The structural com-
plexity of the human BORIS gene in gametogenesis and cancer. PloS one. 2010; 5(11):e13872. doi:
10.1371/journal.pone.0013872 PMID: 21079786
37. Stewart SA, HahnWC, O'Connor BF, Banner EN, Lundberg AS, Modha P, et al. Telomerase contrib-
utes to tumorigenesis by a telomere length-independent mechanism. Proceedings of the National
Academy of Sciences of the United States of America. 2002 Oct 1; 99(20):12606–11. PMID: 12193655
38. Bollmann FM. The many faces of telomerase: emerging extratelomeric effects. BioEssays: news and
reviews in molecular, cellular and developmental biology. 2008 Aug; 30(8):728–32.
39. Kang HJ, Choi YS, Hong SB, Kim KW,Woo RS, Won SJ, et al. Ectopic expression of the catalytic sub-
unit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxic-
ity. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2004 Feb 11; 24
(6):1280–7.
40. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, et al. Telomerase modulates Wnt signalling
by association with target gene chromatin. Nature. 2009 Jul 2; 460(7251):66–72. doi: 10.1038/
nature08137 PMID: 19571879
41. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, et al. Telomerase reverse transcriptase promotes epithelial-mes-
enchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013 Sep 5; 32(36):4203–13.
doi: 10.1038/onc.2012.441 PMID: 23045275
42. Muller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by
beta-catenin signaling. Experimental cell research. 2002 Oct 15; 280(1):119–33. PMID: 12372345
43. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against
the epithelial phenotype? Nature reviews Cancer. 2007 Jun; 7(6):415–28. PMID: 17508028
44. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and
molecular life sciences: CMLS. 2011 Sep; 68(18):3033–46. doi: 10.1007/s00018-011-0735-1 PMID:
21637948
45. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, et al. Expression
of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regu-
lated by three alternative promoters modulated by CpGmethylation and by CTCF and p53 transcription
factors. Nucleic acids research. 2007; 35(21):7372–88. PMID: 17962299
BORIS/CTCFL in Human Cancer Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0132977 July 17, 2015 20 / 21
46. Gaykalova D, Vatapalli R, Glazer CA, Bhan S, Shao C, Sidransky D, et al. Dose-dependent activation
of putative oncogene SBSN by BORIS. PloS one. 2012; 7(7):e40389. doi: 10.1371/journal.pone.
0040389 PMID: 22792300
47. Rosa-Garrido M, Ceballos L, Alonso-Lecue P, Abraira C, Delgado MD, Gandarillas A. A cell cycle role
for the epigenetic factor CTCF-L/BORIS. PloS one. 2012; 7(6):e39371. doi: 10.1371/journal.pone.
0039371 PMID: 22724006
48. Tiffen JC, Bailey CG, Marshall AD, Metierre C, Feng Y, Wang Q, et al. The cancer-testis antigen
BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells. International journal of
cancer Journal international du cancer. 2013 Oct 1; 133(7):1603–13. doi: 10.1002/ijc.28184 PMID:
23553099
BORIS/CTCFL in Human Cancer Stem Cells
PLOS ONE | DOI:10.1371/journal.pone.0132977 July 17, 2015 21 / 21
